Vanta Bioscience Ltd - Stock Valuation and Financial Performance

BSE: 540729 | NSE: | Business Support | Small Cap

Vanta Bioscience Share Price

48.45 0.00 0.00%
as on 01-Oct'24 16:01

DeciZen - make an informed investing decision on Vanta Bioscience

M-Cap below 100cr DeciZen not available

Vanta Bioscience stock performance -

mw4me loader
P/E Ratio (SA):
599.64
Market Cap:
30.6 Cr.
52-wk low:
37
52-wk high:
101.6

Is Vanta Bioscience Ltd an attractive stock to invest in?

1. Is Vanta Bioscience Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Vanta Bioscience Ltd is a below average quality company.

2. Is Vanta Bioscience Ltd undervalued or overvalued?

The key valuation ratios of Vanta Bioscience Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is Vanta Bioscience Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Vanta Bioscience Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Vanta Bioscience:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Vanta Bioscience Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
ROCE % 0%0%0%0%2.5%8.8%8.9%6.8%5.2%-2.4%-
Value Creation
Index
NANANANA-0.8-0.4-0.4-0.5-0.6-1.2-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 00003.912.113.79.89.45.29
Sales YoY Gr.-NANANANA211.3%13.6%-28.4%-4.8%-44.7%-
Adj EPS 0000-00.91.40.80.1-6.70.1
YoY Gr.-NANANANANA64.4%-45.5%-85.9%-6209.1%-
BVPS (₹) 00016.92935.237.137.93831.331.3
Adj Net
Profit
000000.60.90.50.1-4.20
Cash Flow from Ops. 000-0.3-6.8-0.13.2116.70.6-
Debt/CF from Ops. 000-28.3-1.7-215.74.51.63.140-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales NA5.9%-27.8%-44.7%
Adj EPS NANA-267.5%-6209.1%
BVPSNA1.6%-5.6%-17.7%
Share Price - -14.3% -28% 10.1%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
Return on
Equity %
0000-0.12.842.10.3-19.40.3
Op. Profit
Mgn %
000026.627.231.540.236.4-9.2NAN
Net Profit
Mgn %
0000-0.24.66.650.7-820.6
Debt to
Equity
0001.20.70.60.60.70.91.3-
Working Cap
Days
00002352513905774907910
Cash Conv.
Cycle
00001411933194643284840

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 0.30%

Sales growth has been subdued in last 3 years -27.77%

Debt to equity has increased versus last 3 years average to 1.30

Sales growth is not so good in last 4 quarters at 0.00%

Latest Financials - Vanta Bioscience Ltd.

Standalone Consolidated
TTM EPS (₹) 0.1 -3.7
TTM Sales (₹ Cr.) 8.6 9.7
BVPS (₹.) 31.3 27.8
Reserves (₹ Cr.) 13 11
P/BV 1.55 1.75
PE 599.64 0.00
From the Market
52 Week Low / High (₹) 37.00 / 101.64
All Time Low / High (₹) 37.00 / 195.50
Market Cap (₹ Cr.) 30.6
Equity (₹ Cr.) 6.3
Face Value (₹) 10
Industry PE 45.5

Management X-Ray of Vanta Bioscience:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Vanta Bioscience

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Sales03.8812.0813.729.829.355.17
Operating Expenses 02.858.819.415.925.955.65
Manufacturing Costs00.311.171.240.690.740.72
Material Costs00.321.401.180.820.620.68
Employee Cost 01.612.903.792.512.572.75
Other Costs 00.603.333.191.912.011.49
Operating Profit 01.033.274.323.893.40-0.48
Operating Profit Margin (%) -26.6%27.1%31.5%39.7%36.4%-9.2%
Other Income 00.050.230.110.020.170.63
Interest 00.201.691.952.062.113.11
Depreciation 00.570.711.191.251.321.25
Exceptional Items 0000000
Profit Before Tax 00.311.101.290.610.14-4.21
Tax 00.290.400.310.130.060.03
Profit After Tax 00.030.690.980.470.08-4.24
PAT Margin (%) -0.7%5.7%7.1%4.8%0.8%-81.9%
Adjusted EPS (₹)0.00.11.11.60.80.1-6.7
Dividend Payout Ratio (%)0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23

Equity and Liabilities

Shareholders Fund 6.1516.5922.2523.4423.9123.9919.74
Share Capital 3.655.736.316.316.316.316.31
Reserves 2.5010.8615.9317.1317.6017.6813.43
Minority Interest0000000
Debt7.5010.4812.1712.3113.3017.1422.55
Long Term Debt7.509.9812.1710.4310.7715.6420.84
Short Term Debt00.5001.882.531.501.71
Trade Payables00.190.460.490.471.472.36
Others Liabilities 0.101.933.255.508.627.856.98
Total Liabilities 13.7529.1938.1241.7446.3050.4451.64

Fixed Assets

Gross Block12.9518.0619.1823.2333.1141.1643.69
Accumulated Depreciation00.571.282.473.725.046.29
Net Fixed Assets12.9517.4917.9020.7629.3936.1237.40
CWIP 02.343.700000
Investments 04.503.953333
Inventories03.029.2414.019.767.247.16
Trade Receivables00.331.561.361.980.721.92
Cash Equivalents 0.440.090.280.090.070.070.07
Others Assets0.361.421.482.542.103.302.09
Total Assets 13.7529.1938.1241.7446.3050.4451.64

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Cash Flow From Operating Activity -0.26-6.75-0.063.1711.016.700.64
PBT 00.311.101.290.610.14-4.21
Adjustment 00.732.403.143.293.434.36
Changes in Working Capital -0.26-7.8-3.56-1.267.113.130.49
Tax Paid 0000000
Cash Flow From Investing Activity -12.95-7.53-4.48-1.35-9.86-8.05-2.53
Capex -12.95-2.60-2.48-0.35-0.86-8.05-2.53
Net Investments 0-0.0800000
Others 0-4.86-2-1-900
Cash Flow From Financing Activity 13.6613.934.73-2.02-1.171.351.88
Net Proceeds from Shares 6.1510.414.960000
Net Proceeds from Borrowing 7.502.482.19-1.740.341.405.20
Interest Paid 0-0.16-1.69-1.95-2.06-2.11-3.11
Dividend Paid 0000000
Others 0.011.20-0.731.670.552.07-0.21
Net Cash Flow 0.44-0.360.20-0.20-0.0200
PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Ratios
ROE (%)00.243.574.281.990.33-19.37
ROCE (%)02.478.818.866.765.24-2.44
Asset Turnover Ratio00.190.370.350.230.190.1
PAT to CFO Conversion(x)N/A-225-0.093.2323.4383.75N/A
Working Capital Days
Receivable Days0302838615393
Inventory Days0277180301432332508
Payable Days0220851472135661,023

Vanta Bioscience Ltd Stock News

Vanta Bioscience Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Vanta Bioscience on 01-Oct-2024 16:01 is ₹48.45.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 01-Oct-2024 16:01 the market cap of Vanta Bioscience stood at ₹30.58.
The latest P/E ratio of Vanta Bioscience as of 01-Oct-2024 16:01 is 599.6.
The latest P/B ratio of Vanta Bioscience as of 01-Oct-2024 16:01 is 1.55.
The 52-week high of Vanta Bioscience is ₹101.6 and the 52-week low is ₹37.00.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Vanta Bioscience is ₹8.56 ( Cr.) .

About Vanta Bioscience Ltd

Vanta Bioscience (VBS) was originally incorporated as a private limited company under the Companies Act, 2013 pursuant to a certificate of incorporation issued by the Registrar of Companies, Hyderabad dated April 29, 2016 with the name ‘Vanta Bioscience Private Limited’. Their Company was converted into a public limited company pursuant to approval of the shareholders at an extraordinary general meeting held on February 13, 2017 and consequently, the name of the Company was changed to ‘Vanta Bioscience Limited’ and a fresh certificate of incorporation consequent upon conversion to public limited company was issued by the Registrar of Companies, Hyderabad on March 17, 2017.

One of the major services of VBL is conducting variety of in vitro (cell, tissue and organisms) and in vivo (animal) toxicology studies for its diverse clients as per various regulatory requirements from across the world. Toxicology is a branch of biology, chemistry, and pharmacology concerned with the study of the adverse effects of chemicals on living organisms. It also studies the harmful effects of chemical, biological and physical agents in biological systems that establish the extent of damage in living organisms. The relationship between dose and its effects on the exposed organism is of high significance in toxicology. Toxicology and safety assessment are sometimes used interchangeably and considered as synonymous.

Business area of the company

The company is a preclinical contract research organization, offering a host of preclinical safety assessment services for clientele from Pharmaceutical, Medical Devices, Nutraceuticals, Feed Additive, Biotech, Agrochemicals, Cosmetics, and Chemical industries. In addition they also provide risk assessment services for evaluating the safety of the Active Pharmaceutical Ingredients (API), excipients, extractable and leachables including pharmaceutical impurities resulting due to manufacturing process or due to degradation of the product. VBS also provides expert services for determination of health based exposure limits (e.g. permitted daily exposure (PDE) or allowable daily exposure (ADE) including occupational exposure limits (OEL) for pharmaceutical manufacturers. Their services include toxicology, batch release tests, biocompatibility studies, chemical safety, and diet formulation.

Major Events & Milestones:

  • 2016: Incorporation of the Company.
  • 2017:  The Company concluded the purchase of the preclinical CRO facility at Gummidipundi, Chennai from Kemin Industries South Asia Private Limited which was named as - Vanta Bioscience? (a toxicology division of Kemin Industries South Asia Private Limited) along with leasehold rights in 4.8 acres of land situated at Plot K2B, SIPCOT Industrial Estate, Gummidipundi, Chennai - 601 201.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.